Idelalisib and Rituximab in 17p Deletion-Positive Splenic Marginal Zone Lymphoma.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of the National Comprehensive Cancer Network : JNCCN"
DOI: 10.6004/jnccn.2017.7034
Abstract: Splenic marginal zone lymphoma (SMZL) is a rare indolent B-cell malignancy involving the spleen and bone marrow. Various cytogenetic abnormalities with prognostic value have been identified in SMZL. Complexity of karyotype, 14q aberrations, and TP53… read more here.
Keywords: marginal zone; zone lymphoma; idelalisib rituximab; splenic marginal ... See more keywords